Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Add to Collection

2018 Oct 2 Others RJ Mentz, MA Bethel, P Merrill… - Journal of the …, 2018 - Am Heart Assoc 106

Full Author : ['Mentz, Robert J', 'Bethel, M Angelyn', 'Merrill, Peter', 'Lokhnygina, Yuliya', 'Buse, John B', 'Chan, Juliana C', 'Felicio, Joao S', 'Goodman, Shaun G', 'Choi, Jasmine', 'Gustavson, Stephanie M', 'Iqbal, Nayyar', 'Lopes, Renato D', 'Maggioni, Aldo P', 'Ohman, Peter', 'Pagidipati, Neha J', 'Poulter, Neil R', 'Ramachandran, Ambady', 'Reicher, Barry', 'Holman, Rury R', 'Hernandez, Adrian F']
Journal Title : Journal of the American Heart Association
Chapter : Section3
Journal Year : 2018
Cited by : 19.0

Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause mortality in 14 752 patient..... Read More

Keywords : ["type diabetes mellitus insight", "clinical outcome accord", "onceweekly exenatide", "exscel trial", "baseline risk", "patient", "effect"]
PubMed Link : https://www.ahajournals.org/doi/abs/10.1161/JAHA.118.009304
Google Scholar Link : https://scholar.google.com/scholar?cites=8312327904257046632&as_sdt=5,47&sciodt=0,47&hl=en&num=20

Have a Question?

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.